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Abstract
Background: Aim of this study was to evaluate functional outcomes of transanal total mesorectal excision (TaTME)
in comparison to conventional laparoscopic approach (LaTME) in terms of low anterior resection syndrome (LARS).
Methods: Forty-six patients who underwent total mesorectal excision for low rectal cancer between 2013 and 2017
were enrolled. Primary outcome was the severity of faecal incontinence, assessed both before the treatment and 6
months after ileostomy reversal. LARS score and Jorge-Wexner scale were utilized to analyze its severity.
Results: Twenty (87%) from TaTME and 21 (91%) from LaTME group developed LARS postoperatively. There were
no significant differences between groups in terms of LARS occurrence (p = 0.63) and severity. The median Wexner
score was comparable in both groups (8 [IQR: 4–12] vs 7 [3–11], p = 0.83). Univariate analysis revealed that
postoperative complications were a risk factor for LARS development (p = 0.02). Perioperative outcomes, including
operative time, blood loss and intraoperative adverse events did not differ significantly between groups either. Five
TaTME patients developed postoperative complications, while there were morbidity 6 cases in LaTME group. Quality
of mesorectal excision was comparable with 20 and 19 complete cases in TaTME and LaTME groups, respectively.
Conclusions: TaTME provided comparable outcomes in terms of functional outcomes in comparison to LaTME for
total mesorectal excision in low rectal cancers. Having said that, LARS prevalence is still high and requires further
evaluation of the technique.
Keywords: Functional outcomes, Faecal incontinence, Transanal approach, Low anterior resection syndrome, Total
mesorectal excision
Background
Low anterior resection with primary anastomosis is fre-
quently associated with a set of postoperative symptoms,
referred to as low anterior resection syndrome (LARS)
[1]. The incidence and severity of LARS varies in differ-
ent studies. It can reach up to 90% in patients undergo-
ing rectal cancer treatment, among whom up to 60%
will develop major LARS [2–4]. Among suggested etio-
logic factors, damage of autonomic nerves related to
neoadjuvant radiation therapy and surgical procedures
are mentioned [5].
Introduction of minimally invasive techniques (either
laparoscopic or robotic) to rectal cancer surgery im-
proved short-term clinical outcomes, including reduced
length of stay (LOS), surgical site infection rate and
postoperative pain, while maintaining similar oncological
outcomes [6–9]. Although this approach facilitates bet-
ter visualization of the operative field, especially regard-
ing pelvic nerves, no improvement in terms of LARS has
been noted so far [10].
A novel, transanal approach to total mesorectal exci-
sion (TaTME) is believed to be at least non-inferior al-
ternative in terms of oncological results for open and
laparoscopic resections [11]. However, concerns have
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been risen about the influence of transanal approach,
combined with extensive dissection of pelvic structures,
on postoperative function of anal sphincters [12]. This
aspect of TaTME has not been studied so far.
We designed this study to evaluate functional out-
comes of TaTME in comparison to conventional laparo-
scopic total mesorectal excision (LaTME) in terms of
LARS.
Methods
Setting and design
Between 2013 and 2017 a prospective database of pa-
tients undergoing total mesorectal excision for rectal
cancer was developed. All subjects were patients in ter-
tiary referral university hospital with annual volume of
approximately 50 cases. TaTME was introduced in 2014
year. In 2015, TaTME technique was introduced to the
department’s clinical practice as a standard procedure.
We excluded first 10 cases from the analysis due to
avoid bias related to the learning curve. We are COLOR
III study approved centre. LaTME group was recruited
from patients operated between 2013 and 2015. Only pa-
tients with low rectal cancer (up to 5 cm from the anal
verge) were included. Patients requiring abdominoperineal
resection (cancer infiltration on external anal sphincter
persistent after neoadjuvant chemoradiotherapy) were
excluded from the analysis. Chemoradiotherapy was used
in patients initially assessed as T3 and T4 or N+ in MRI
examination. We routinely use long courses of radiother-
apy with a total dose of 50.4 Gy and concomitant chemo-
therapy, which contains 38-day course of capecitabine.
The resection is scheduled 8 weeks after the neoadjuvant
treatment completion. All procedures were performed by
a team of experienced surgeons with expert skills in lap-
aroscopic surgery, who had been trained in TaTME tech-
nique during cadaver-based courses. During the study
period, the main operator was the same surgeon in all
cases.
For the purpose of this study, faecal incontinence was
assessed twice: before the start of the neoadjuvant treat-
ment and 6months after ileostomy reversal. To stratify
its severity, we used LARS score and Jorge-Wexner scale
[1, 13]. The questionnaires were collected prospectively
by a member of surgical team during a visit in an out-
patient clinic. Clavien-Dindo scale was used for report-
ing perioperative complications [14].
Operative technique
The method of performing LaTME implemented in our
department is described elsewhere [15]. In TaTME cases,
we used a modified technique with application of Karl
Storz TEO platform instead of GelPOINT Path Trananal
Table 1 Demographical characteristics
LaTME TaTME p value
Number of patients 23 23 –
Age (median, IQR) 64 [58–67] 60 [51–67] 0.41
Sex (women) 10 (31%) 10 (31%) 0.37
BMI (kg/m2; median, IQR) 26.5 [23.8–30.6] 26 [22.8–29.7] 0.43
Distance of the tumor from the anal verge (cm; median, IQR) 4 [3–5] 3[2–4] 0.01
ASA I/II/III 2/16/5 3/15/6 0.60
Preoperative neoadjuvant treatment (yes/no) 19/4 18/5 0.71
Adjuvant treatment (yes/no) 15/8 13/10 0.54
Type of anastomosis
(stapled/hand-sewn)
21/2 21/2 1.00
Clinical TNM before neoadjuvant treatment
cT1/2/3/4 3/6/12/2 2/3/15/3 0.24
cN 13/23 14/23 0.76
Postoperative LARS incidence
No LARS 2 (9%) 3 (13%) 0.63
Minor LARS 9 (39%) 12 (52%) 0.37
Major LARS 12 (52%) 8 (35%) 0.23
Preoperative LARS Score (median, IQR) 0 [0–5] 5 [0–21] 0.10
Postoperative LARS score (median, IQR) 30 [21–34] 29 [24–34] 0.76
Preoperative Wexner (median, IQR) 0 [0–1] 0 [0–2] 0.20
Postoperative Wexner (median, IQR) 7 [3–11] 8 [4–12] 0.83
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Access Platform, that is used by most teams. We rou-
tinely use one-team approach. The anastomoses were
performed with circumferential mechanical stapler or
were hand sewn in case it was impossible to use stapler
due to low level of the anastomosis. In TaTME patients,
the purse string suture before anastomosis was done
with TEO TEM platform. 33 or 31 mm circumferential
stapler was used, depending on the bowel diameter. In
all cases straight anastomosis was performed, with no
modifications such as coloplasty or j-pouch. Defunction-
ing ileostomy was executed in all cases. In case of mani-
festation of anastomotic leakage (clinical, radiological or
endoscopic), laparoscopic lavage with pelvic drainage
was performed. Also, intraoperative colonoscopy was
done with application of EndoVac negative pressure
wound treatment therapy. If there was no clinical evi-
dence of anastomotic leakage, a colonoscopic examin-
ation was scheduled 3 weeks after initial surgery, in
order to confirm proper healing of the anastomosis.
Additionally, the test of the anal sphincter function was
performed (digital rectal examination, liquid continence
after enema application). The date of ileostomy reversal
was scheduled when there was no leakage found. Every
patient was treated according to Enhanced Recovery
After Surgery protocol [16, 17].
Measured outcomes
Primary outcome was the severity of fecal incontinence
measured with LARS score and Jorge-Wexner scale. The
assessment was done twice – before the treatment and
6months after ileostomy reversal. LARS was classified as
major when patient scored at least 30 points and as
minor with 21–29 points [1]. Secondary outcomes were
perioperative features: operative time, blood loss, num-
ber of intraoperative adverse effects, number of compli-
cations and pathological quality of the resected
specimen. Pathological assessment was performed ac-
cording to Quirke criteria [18].
Statistical analysis
All data were analyzed with Statistica version 13.0 PL
(StatSoft Inc., Tulsa, OK, USA). Continuous results are
presented as median and interquartile range (IQR). Cat-
egorical variables were compared by chi-square test. The
Shapiro-Wilk test was used to check for normal distribu-
tion of data, and Student’s t-test was used for normally
distributed quantitative data. For non-normally distrib-
uted quantitative variables, Mann-Whitney U test was
used. A p-value < 0.05 was considered statistically sig-
nificant. All considerable patient- and treatment-related
factors were analyzed with logistic regression models in
search of risk factors for LARS.
The study was approved by the local ethics committee.
Each patient signed an informed consent before inclu-
sion in the study.
Results
Fourty-six patients were included to the analysis. Demo-
graphic characteristics are presented in Table 1.
Median preoperative LARS score were 0 (IQR: 0–5)
and 5 (0–21) in LaTME and TaTME groups, respectively.
Table 2 Univariate risk factors analysis for LARS score and
Jorge-Wexner scale
Univariate risk factors analysis for LARS scale
OR 95% CI p value
Females vs. Males 0.84 0.26–2.68 0.767
Age 0.95 0.89–1.02 0.192
BMI 0.92 0.80–1.06 0.253
TaTME vs. LaTME 0.84 0.26–2.67 0.768
Depth 0,81 0.81–0.53 0.342
Radiotherapy 1.27 0.33–4.95 0.730
Anastomosis type
(Stapled vs handsewn)
4,63 0.46–45.97 0.187
IAE 0.76 0.18–3.28 0.711
Operative time 1.00 0.99–1.01 0.712
Blood loss 0.998 0.995–1.002 0.406
Complications 6.75 1.27–36.03 0.025
cT 0.87 0.42–1.80 0.714
pT 1.21 0.74–2.00 0.451
AJCC 1.12 0.66–1.89 0.687
Adjuvant treatment 1.00 0.43–2.30 0.99
Univariate risk factors analysis for Jorge-Wexner scale
Parameter ± SD p value
Females vs. Males 0.562 ± 1.074 0.605
BMI 0.120 ± 0.224 0.595
TaTME vs. LaTME 0.723 ± 1.167 0.541
Depth 0.511 ± 0.695 0.468
Radiotherapy 1.129 ± 1.120 0.322
Anastomosis
(Stapled vs handsewn)
0.240 ± 1.036 0.817
IAE 1.181 ± 1.390 0.402
Operative time 0.019 ± 0.020 0.350
Blood loss 0.005 ± 0.007 0.496
Complications 1.268 ± 1.109 0.262
cT 0.30 ± 0.970 0.755
pT 1.080 ± 0.945 0.262
AJCC 0.19 ± 0.710 0.785
Adjuvant treatment 0.242 ± 1.520 0.757
Notes: Abbreviations: OR, Odds ratio; CI, Confidence interval; IAE, Intraoperative
adverse events
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There were no significant differences between the
groups (p = 0.10). Median Wexner score was 0 (0–1) in
LaTME and 0 (0–2) in TaTME group and the results
were also not statistically significant (p = 0.20). None of
the patients in LaTME group suffered from fecal incon-
tinence. Two TaTME patients had minor, and one pa-
tient minor LARS preoperatively.
In postoperative evaluation, 20 (87%) patients from
TaTME group developed LARS, whereas in LaTME
group 21 (91%) patients were affected by it (p = 0.63). 8
patients (35%) in TaTME group developed major LARS,
whereas there were 12 individuals (52%) in LaTME
group. There were no significant differences between
groups (p = 0.23). 12 patients (52%) in TaTME group
and 9 (39%) patients in LaTME group had minor LARS
(p = 0.37). In univariate analysis, only postoperative com-
plications occurred to be a risk factor for LARS develop-
ment (p = 0.02, OR: 6.75, 95% CI 1.26–36.03). As
univariate analysis identified only one risk factor of
LARS we did not perform multivariate analysis of logis-
tic regression.
Median Wexner score after the end of treatment was 7
in LaTME (IQR: 3–11) and 8 in TaTME group (IQR: 4–
12) and did not differ significantly (p = 0.83). No risk fac-
tors were identified in univariate analysis (Table 2).
Differences in operative time: 212 (IQR: 180–250) mi-
nutes - LaTME vs. 252 (IQR: 190–300) - TaTME were
not statistically significant (p = 0.14). Both groups were
also comparable (p = 0.58) regarding blood loss: 100
(IQR: 50–100) ml and 100 (IQR: 50–250) ml in LaTME
and TaTME groups, respectively. 3 (13%) intraoperative
adverse events (IAE) occurred in LaTME group (1 intra-
operative bleeding, 2 intraoperative anastomotic leakage
which was repaired during the procedure). In TaTME
group there were 4 (17%) IAE (2 purse string failures, 1
intraoperative anastomotic leak and 1 intraoperative
bleeding). There were no statistical differences between
the groups (p = 0.68).
Six patients from LaTME group and 5 patients from
TaTME group suffered from postoperative complications,
including four severe cases (Clavien-Dindo III-V) in each
group. The summary of perioperative morbidity is pre-
sented in Table 3.
In 20 cases (86%) in TaTME group the quality of mesorec-
tal excision was assessed as complete. In the remaining 3
(14%) cases, mesorectal excision was nearly complete. In
LaTME group, 19 (83%) patients had complete and 4 nearly
complete excisions. One patient in TaTME group (4,5%) had
positive circumferential resection margin (CRM) and one
patient in LaTME group (4,5%) had positive distal resection
margin (DRM). These results of pathological outcomes are
summarized in Table 4.
Discussion
In our study we presented functional outcomes of low rec-
tal resections using LaTME and TaTME techniques. Al-
though the clinicopathological outcomes are acceptable,
faecal continence is still far from satisfactory. Still, both
techniques were comparable in terms of functional
outcomes.
Oncological outcomes are of utter importance in rectal
cancer treatment, yet patient’s quality of life should also
be a matter of further discussion [19, 20]. Available stud-
ies do not focus on functional outcomes of TaTME.
COLOR III – a Randomized Control Trial comparing
LaTME and TaTME has functional assessment in the
study protocol, but the results are expected to be re-
leased after 2020 [21]. Fecal incontinence is the element
of LARS with the highest impact on quality of life in
terms of social and professional life [22]. Surprisingly, ir-
reversible loss of sphincter during abdomino-perineal
(APR) resection is comparable to sphincter saving sur-
gery regarding quality of life [22]. So far, we can present
only short-term results, and we may expect that proper
rehabilitation may improve the function of anal sphinc-
ters [23]. However, as pointed by other authors this im-
provement can be achieved only during first year after
surgery and is more likely to be related to higher accept-
ance of symptoms than real recovery of continence [19].
Table 3 Perioperative morbidity
Clavien-Dindo LaTME N (%) TaTME N (%)
V – 0 – 0
IV – 0 Intraabdominal abscess, sepsis 1 (4.5%)
IIIb Anastomotic leakage (operative treatment) 2 (9%) Anastomotic leakage 2 (9%)
Postoperative ileus (operative treatment) 2 (9%)
IIIa – 0 – 0
II High output stoma
Anastomotic lekeage (conservative treatment)
1 (4.5%)
1 (4.5%)
Postoperative ileus (conservative treatment) 1 (4.5%)
I – 0 – 0
Total 6 (26%) 4 (17%)
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The literature about functional outcomes of TaTME is
extremely limited. Only one recent study published by
Veltcamp et al. focused on patients’ quality of life [24].
Although authors failed to document significance (prob-
ably due to low study sample), the incidence of major
LARS reached 30% in LaTME group and almost 60% in
TaTME group. On the contrary, Elmore and Chen ob-
tained acceptable results, however in this case only
Wexner scale with median 8 points was used and au-
thors stated that all patients were fully continent [25,
26]. In both of these studies the study group was very
small including 6 cases. Therefore, further studies are re-
quired to evaluate TaTME functional outcomes.
In our research, only postoperative complications oc-
curred to be a risk factor for LARS development. Bregen-
dahl also points on anastomotic leakage as a factor
predisposing for LARS [27]. Other authors underline the
significance of neoadjuvant and adjuvant radiotherapy as a
common risk factor for faecal incontinence [28, 29]. Also,
defunctioning ileostomy may contribute to LARS [29]. What
is important, extending time for ileostomy reversal beyond
6months will also increase the rate of fecal incontinence
[30]. Next, the distance of the tumor from the anal verge is
a well known risk factor of LARS development [19]. Type of
anastomosis may also affect functional outcomes in favor of
stapled anastomosis versus hand-sewn [22]. As mentioned,
Veltcamp published the first study comparing TaTME and
LaTME, however, majority of patients were operated due to
tumors of middle rectum, between 5 and 10 cm from the
anal verge [24]. Our study is the first one to assess only low
rectal resections, less than 5 cm from the anal verge.
Clinical and pathological outcomes of TaTME ap-
pear to be comparable to LaTME. Many authors sug-
gested that TaTME may enable achieving wider CRM,
although available meta-analyses present equivocal
data [31–33]. Our series is too small to find evidence
supporting this important aspect and this may be
expected from the results of the ongoing, large ran-
domized control trials [21, 34].
Our study has some obvious limitations. Firstly, the
number of cases is limited which does not allow us to
draw any strong conclusions. We also used question-
naires (Wexner scale and LARS score), but did not
perform functional outcome analysis with electromyog-
raphy or sphincter manometry, which could be useful in
sphincter insufficiency detection. Having said that, LARS
score and Jorge-Wexner scale are based on patient’s own
view, which is helpful to understand and predict their
quality of life [5, 12]. Furthermore, LaTME group con-
sisted of patients with tumors localized slightly higher
from the anal verge than in TaTME group. Nevertheless,
both groups assessed only low rectal tumors, less than 5
cm from the anal verge.
Conclusions
TaTME is a promising technique and provides compar-
able results to LaTME in regards to functional outcomes
in low rectal cancer resections. Although clinical and
pathological outcomes are satisfactory, the prevalence of
LARS remains high and further evaluation of this tech-
nique is required.
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